ITCI - Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15 revenue of $55.6M beats by $6.98M

• Intra-Cellular Therapies press release ( NASDAQ: ITCI ): Q2 GAAP EPS of -$0.92 misses by $0.15 .
• Revenue of $55.6M (+177.3% Y/Y) beats by $6.98M .
• Cash, cash equivalents, restricted cash and investment securities totaled $679.2M at June 30, 2022, compared to $413.7M at December 31, 2021.
• CAPLYTA net product revenues for the second quarter 2022 were $55.1M, representing a 190% increase over the same period in 2021 and a 58% increase over the first quarter 2022 .
• Second quarter 2022 CAPLYTA new and total prescriptions increased 225% and 191%, respectively, versus the same period in 2021 .
• Second quarter 2022 CAPLYTA new and total prescriptions increased 55% and 51%, respectively, versus the first quarter 2022 .

For further details see: